APUS vs L · $2.4M cap vs P/E 14, rev $18.45B
Apimeds Pharmaceuticals US, Inc. (APUS) versus Loews Corp (L) — a side-by-side from cached financials, not a winner call.
Apimeds Pharmaceuticals US, Inc. (APUS) is a drug manufacturers - specialty & generic company listed on US.
Loews Corp (L) is a insurance - property & casualty company listed on NYSE.
APUS does not have a complete income-statement cache yet.
Latest reported L revenue for 2025-12-31 was $18.45B. Net income was $1.67B. Revenue was up 5.4% from 2024-12-31 to 2025-12-31. L currently screens at market cap $22.36B and trailing P/E 13.8.
APUS currently screens at market cap $2.4M. L currently screens at market cap $22.36B and trailing P/E 13.8.
Not investment advice. Open the APUS and L stock pages for the full models.
Not investment advice.